Acrivon Therapeutics, Inc. Common Stock (ACRV) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Acrivon Therapeutics, Inc. Common Stock (ACRV) has a cash flow conversion efficiency ratio of -0.096x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-12.28 Million) by net assets ($128.60 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see Acrivon Therapeutics, Inc. Common Stock stock valuation for the company's overall valuation and market capitalisation.
Acrivon Therapeutics, Inc. Common Stock - Cash Flow Conversion Efficiency Trend (2020–2024)
This chart illustrates how Acrivon Therapeutics, Inc. Common Stock's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Acrivon Therapeutics, Inc. Common Stock Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Acrivon Therapeutics, Inc. Common Stock ranked by their cash flow conversion efficiency. See ACRV operating cash to total liabilities to evaluate how effectively operating cash flow covers total debt obligations.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Gray Television Inc
NYSE:GTN-A
|
0.000x |
|
Coxon Precise Industrial Co Ltd
TW:3607
|
-0.017x |
|
JC Chemical Co. Ltd
KQ:137950
|
0.093x |
|
SDS Group Bhd
KLSE:0212
|
0.047x |
|
Bina Puri Holdings Bhd
KLSE:5932
|
-0.332x |
|
Bilendi
PA:ALBLD
|
0.110x |
|
Fire & Gas Detection Technologies Ltd
TA:FGAS
|
-0.079x |
|
Hansol Csn
KO:009180
|
0.030x |
Annual Cash Flow Conversion Efficiency for Acrivon Therapeutics, Inc. Common Stock (2020–2024)
The table below shows the annual cash flow conversion efficiency of Acrivon Therapeutics, Inc. Common Stock from 2020 to 2024. View Acrivon Therapeutics, Inc. Common Stock stock quote for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $176.79 Million | $-65.67 Million | -0.371x | -5.58% |
| 2023-12-31 | $121.19 Million | $-42.64 Million | -0.352x | -99.16% |
| 2022-12-31 | $170.47 Million | $-30.12 Million | -0.177x | -130.08% |
| 2021-12-31 | $-23.81 Million | $-13.98 Million | 0.587x | +76.26% |
| 2020-12-31 | $-8.41 Million | $-2.80 Million | 0.333x | -- |
About Acrivon Therapeutics, Inc. Common Stock
Acrivon Therapeutics, Inc., a clinical stage biopharmaceutical company, discovers and develops oncology medicines for patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its generative phosphoproteomics platform. The company operates Acrivon Predictive Precision Proteomics (AP3), a precision medicine platform that enables the creation of drug specific propri… Read more